We appreciate the comments of Drs Alrajab and Abu Baker about our recent article in CHEST (November 2010).1 The question they raise about whether pulmonary hypertension (PH) without left ventricular dysfunction (LVD) was significantly different in survival rates from PH and LVD is well taken. We found that the survival rates were different for patients with PH, with those patients without LVD having worse survival rates. The differences were most apparent with longer follow-up periods, and this may be because of the inclusion of patients with PH and LVD who had caridomyopathy. We did acknowledge this in our article and took pains to try to clarify that the differences were due to hemodynamics rather than associated factors. We agree that other factors, including treatment, may influence the outcome. We believe our report should stimulate interest in developing a prospective study of PH in sarcoidosis to test the importance of the other factors listed by Drs Alrajab and Abu Baker.